Verastem Inc. reported $25.1 million in net product revenues for Q2 2026 from its Avmapki Fakzynja Co-pack, used for certain ovarian cancer patients. The company is also developing a KRAS G12D inhibitor, VS-7375, targeting multiple cancers, with important clinical trial results from the TARGET-D 101 study expected in October. This upcoming data readout represents a significant near-term catalyst for the company. Additionally, GenFleet Therapeutics, also developing VS-7375, will provide updated data in the same timeframe, highlighting ongoing progress in this cancer treatment area.
Verastem's upcoming clinical readout and commercial launch are noted here with Pluang's health sector data as of Oct 06, 2026 14:12 WIB. Of 100 priced health-sector US stocks tradable on Pluang, 69 rose and 27 fell today. Notable movers include ADMA Biologics Inc at USD 10.10 with a 3.91% increase and a typical hold time of 17 days, Stryker Corporation at USD 285.17 up 3.54%, and Cassava Sciences Inc at USD 0.90 rising 3.46%, with Pluang order activity heavily favoring selling for ADMA and Stryker but buying for Cassava Sciences.
Elon Musk has confirmed that his company is in discussions with Terafab, marking a potential new chip manufacturing partner alongside Intel, which has been the only named chip partner until now. This development could diversify the supply chain and e...
Radiant Uranium has finalized its acquisition of the 2,048-hectare Cross Lake uranium property in Saskatchewan's Athabasca Basin by issuing 4 million shares and paying $20,000 to Bromell Mining LLP. The property contains a historic uranium estimate o...
One year after reaching a record high of over $126,000 in October 2025, Bitcoin's price has dropped just 32% to around $85,453, a much smaller decline compared to previous bear markets where drops ranged from 70% to over 80%. This milder downturn is ...
The Solana Foundation introduced Solana DvP, an open-source protocol that enables financial institutions to complete trade settlements on blockchain within seconds instead of days. Developed with guidance from JPMorgan, the protocol replaces fragment...
SpaceX shares surged 15.55% in just five days, driven by multiple positive developments including the company's rebranding of its AI division to 'super intelligence,' successful Starship launches, and Elon Musk's return to a leadership role in the Pe...
